CoChat

No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

Open access
Lunt, Mark, Watson, Kath D., Dixon, William G., British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons, Deborah P. M., Hyrich, Kimme L., British Society for Rheumatology Biologics Register · 2010 · Arthritis & Rheumatism
Cited by 82

The DOI matches its Crossref record.

Abstract

Objective: To study the association between anti–tumor necrosis factor (anti‐TNF) therapy and mortality in a national cohort of patients with rheumatoid arthritis. Methods: We prospectively followed up 12,672 patients who were beginning anti‐TNF therapy and 3,522 biologic‐naive patients receiving disease‐modifying antirheumatic drugs (DMARDs) until either July 31, 2008, or death, whichever occurred first. Notification of death and cause of death was received from the UK National Death Register. Mortality was compared using Cox proportional hazards models. Inverse probability of treatment weighting was used to adjust for the confounding effects of baseline differences between groups, including age, sex, disease severity, disability, and comorbidity. Missing baseline data were accounted for using multiple imputation. Results: When compared with the DMARD cohort, the anti‐TNF cohort was younger (median age 57 years versus 61 years), had greater disease activity (median Disease Activity Score in 28 joints 6.6 versus 5.1), and had greater disability (median Health Assessment Questionnaire score 2.1 versus 1.6). Patients in the DMARD cohort were more likely to have a history of myocardial infarction (4.8% versus 3.1%) and chronic obstructive pulmonary disease (8.1% versus 4.8%) but were less likely to have had depression (16.5% versus 18.9%). There were 9,445 and 50,803 person‐years of followup in the DMARD and anti‐TNF cohorts, respectively, during which time 204 DMARD‐treated and 856 anti‐TNF–treated patients died. The weighted mortality hazard ratios in the anti‐TNF cohort were as follows: all‐cause 0.86 (95% confidence interval [95% CI] 0.64–1.16), circulatory disease 0.73 (95% CI 0.44–1.23), neoplasm 0.65 (95% CI 0.39–1.09), and respiratory disease 0.81 (95% CI 0.36–1.83). Conclusion: Our results indicate that, compared with standard DMARD therapy, treatment with anti‐TNF therapies was not associated with an increase in mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27660

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Lunt, M., Watson, K. D., Dixon, W. G., British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons, D. P. M., Hyrich, K. L., & British Society for Rheumatology Biologics Register
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-10-29
Volume
62
Issue
11
Pages
3145-3153
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2044143470
Cited by
82
References
0
FWCI
8.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.